Ben has more than 20 years of experience working in biopharma business development and M&A, and pipeline and launch strategy.

Ben’s primary focus is working with emerging and smaller growth-stage biopharma clients. He has collaborated with over 50 biopharma companies to prepare for their initial product launches and has extensive experience providing strategic guidance at the intersection of new product development and commercialization. Ben has worked in all major therapeutic areas—and is particularly extensive in oncology, immunology, CNS and rare diseases. Ben is a regular speaker on first product launches and partnerships, and has presented at several industry conferences, including Bio International, Bio Europe, LSX World Congress and J.P. Morgan’s Healthcare Conference.

Ben’s areas of expertise include preparing to launch, emerging biopharma first launch, global opportunity assessment and valuation, therapeutic area strategy, disease and condition strategy, pipeline life cycle management and optimization, asset and company due diligence, asset/technology and company identification for licensing or acquisition, market entry strategy, and innovation and growth strategy.

Prior to ZS, Ben was a partner at Monitor Group, the founder of Hohn & Company, and a principal at ISO Healthcare Consulting.

Ben holds an MBA from Boston University with the highest honors and a bachelor’s in economics and pre-med from Vassar College.